Navigation Links
ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR

>

About ZIO-101

ZIO-101 is a proprietary small molecule organic arsenic licensed from The University of Texas M. D. Anderson Cancer Center and Texas A&M University. ZIO-101 induces cell cycle arrest and cell death by targeting several cellular pathways essential for cell survival. Exposure to ZIO-101 has a direct as well as indirect effect on mitochondrial functions, resulting in depletion of energy supply to the cell and induction of apoptosis (programmed cell death). Increase in intra-cellular Reactive Oxygen Species enhances this effect on mitochondrial functions and consequently the activation of the signal transduction pathway leading to apoptosis. In addition, ZIO-101 interrupts the cell cycle at the G2/M phase of tumor cells inducing cell death through this pathway as well.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its prod
'"/>




Page: 1 2 3

Related medicine technology :

1. ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
3. ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR
4. ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ZIOPHARM Presents Data Highlighting Oral ZIO AACR
(Date:9/4/2015)... Texas , Sept. 4, 2015  Luminex Corporation ... present at the Morgan Stanley Global Healthcare Conference to ... Grand Hyatt Hotel in New York City ... at 11:40 a.m. Eastern time on Friday, September 18, ... accessed at Luminex Corporation,s website at http://www.luminexcorp.com . ...
(Date:9/4/2015)... 4, 2015 According to a ... Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Billion by 2020, growing at a CAGR of 11.2% ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... upcoming Rodman & Renshaw 17 th Annual Global ... New York City .  Dr. Michael ... overview on September 9, 2015. Presentation ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... 2011 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... EST on Friday, January 6, 2012 at the Millennium Hotel, ... Executive Officer, Patrick G. LePore, and other members of the ... growth strategy, current products and pipelines, and business outlook to ...
... Calif., Dec. 5, 2011  Beyond Lucid Technologies, Inc., ... disaster management, and First Response industries, today announced ... the mHealth Summit, and the publication of a ... connect ambulances with hospitals via telemedicine. ...
Cached Medicine Technology:Beyond Lucid Technologies Advances Telemedicine for EMS Providers 2Beyond Lucid Technologies Advances Telemedicine for EMS Providers 3
(Date:9/4/2015)... ... September 04, 2015 , ... Mile High Connects today releases “First ... lack of funding for sidewalks, bike paths, and other vital supports severely limit access ... region spends billions of dollars to expand public transit, there’s very little support for ...
(Date:9/4/2015)... ... 2015 , ... After wearing the same uniforms for six seasons, the Sprayberry ... effort to assist the team, the Jones Agency, a locally owned insurance firm that ... for the new uniforms. , As is so often the case with high school ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... that CEREC technology is now available at CitiDent. CEREC is a newer method ... addition to saving time for patients by eliminating the need for multiple appointments, ...
(Date:9/4/2015)... ... 04, 2015 , ... The USC Eye Institute is proud to announce that ... Faculty, residents and staff are honored to have contributed to the success of ... ophthalmology residency program. Our faculty places a high priority on our educational programs in ...
(Date:9/4/2015)... ... September 04, 2015 , ... Steven ... South Glastonbury, Connecticut, has been selected for the Residential Award of Merit by ... and resiliency measures. Chosen from a highly competitive field of submissions, the net-zero ...
Breaking Medicine News(10 mins):Health News:Missed Connections in Metro Denver Transit 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2
... WOODBURY, N.Y., Aug. 3 COMFORCE Corporation (NYSE Amex: ... specialty staffing and consulting services, today announced that it will report ... to market opening. , , COMFORCE will sponsor ... Eastern Time, hosted by John Fanning, Chairman and Chief Executive Officer, ...
... INCLINE VILLAGE, Nev., Aug. 3 PDL BioPharma, Inc. (PDL) (Nasdaq: ... ("Barry") Selick, Ph.D., to the Company,s Board of Directors. , ... his extensive knowledge of PDL,s humanization technology will allow him to ... to maximize the value of our antibody humanization patents and related ...
... , SAN DIEGO and ... privately held pharmaceutical company and Astellas Pharma US, Inc. ... DosePro (sumatriptan injection) needle-free delivery system. Sumavel DosePro ... first-of-its-kind needle-free delivery system for subcutaneous sumatriptan, a treatment ...
... PHOENIX, Ariz. Aug. 1, 2009 An international ... (TGen) has received a $1 million grant to study ... grant was made to a team led by Dr. ... the Team Lead among the Principal Investigators in the ...
... , , WALTHAM, Mass., Aug. ... and advisory firms for pharmaceutical and healthcare issues, finds that, ... tamsulosin--will cause a decline of more than eight percent in ... urinary tract symptoms in the United States, France, Germany, Italy, ...
... ARDEE, Ireland, Aug. 3 Warner Chilcott Limited (Nasdaq: ... Paragraph IV Certification Notices from Lupin Ltd. ("Lupin"). The Paragraph ... New Drug Applications (ANDAs) by Lupin for generic versions of the ... , LOESTRIN 24 FE, which was launched in ...
Cached Medicine News:Health News:COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 2Health News:PDL BioPharma Elects Barry Selick to Its Board of Directors 2Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 2Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 3Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 4Health News:TGen-led team is 1 of 7 selected for $1 million skin-cancer grants 2Health News:TGen-led team is 1 of 7 selected for $1 million skin-cancer grants 3Health News:TGen-led team is 1 of 7 selected for $1 million skin-cancer grants 4Health News:Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms 2Health News:Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms 3Health News:Warner Chilcott Announces Receipt of Paragraph IV Certification Notices 2Health News:Warner Chilcott Announces Receipt of Paragraph IV Certification Notices 3
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: